This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.
It is an all-hands-on-deck type of situation at Intel, where the former behemoth of the semiconductor sphere is now trying to conserve cash by slashing dividends and payrolls, and attempting to raise additional funding by culling extraneous investments. A case in point: Intel has now sold all of its stake in Arm Holdings.
As we've noted in a number of recent posts, Intel is traversing a multidecadal nadir at the moment, having failed to meet the consensus expectations of analysts for its top-line and bottom-line metrics in Q2 2024, and compounding this failure by posting underwhelming results for the key DCAI segment, which indicates that it has yet to truly tap into the secular AI-focused tailwind.
Critically, Intel missed its own guidance for the just-concluded quarter's gross margin by a wide shot and guided to further sequential weakness ahead.
To conserve cash, the company has cut its dividend and announced another mass layoff plan, to the tune of 15,000 employees, or 13.6 percent of its current workforce of around 110,000. This follows the 5 percent layoff that the company implemented just last year.
This brings us to the crux of the matter. Intel has now filed a Form 13-F with the SEC, indicating that it has disposed of the entirety of its Arm Holdings stake, which comprised of 1.18 million shares as of Q1 2024.
Interestingly, the chip manufacturer still retains a stake in Astera Labs (NASDAQ: ALAB), Joby Aviation (NYSE: JOBY), MariaDB (NYSE: MRDB), and Senti Biosciences (NASDAQ: SNTI).
Bear in mind that Intel has recognized a cumulative loss of $120 million on its equity investments in Q2 2024. This line item on the income statement includes both realized and unrealized gains/losses (arising from changes in the fair value
Read more on wccftech.com